AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (ABCL) reported Q1 2021 financial results, showcasing a remarkable 4253% increase in total revenue, reaching $202.7 million compared to $4.7 million in Q1 2020. Key highlights include $171.5 million in royalty revenue from bamlanivimab and $117.2 million in net earnings, a significant recovery from a $2.1 million loss the previous year. The company expanded its partnership portfolio, achieving 119 programs under contract with 29 partners. R&D expenses rose to $12.4 million, reflecting robust investments in discovery capabilities.
AbCellera (Nasdaq: ABCL) has announced that its executives will present virtually at the Berenberg Conference USA 2021 on May 18, 2021, at 11:00 a.m. Pacific Time. A live audio webcast will be available through AbCellera’s Investor Relations website, with a replay accessible afterward.
AbCellera is a technology company focused on analyzing natural immune systems to discover antibodies for drug development. The company supports both large pharmaceutical and small biotechnology partners, enabling efficient and cost-effective drug development.
AbCellera (Nasdaq: ABCL) and Angios GmbH have announced a multi-year collaboration focused on discovering monoclonal and bispecific antibodies for eye vascular diseases, particularly diabetic retinopathy. AbCellera will leverage its AI-powered platform to create antibody panels for up to three targets selected by Angios. This partnership allows Angios to expedite their therapeutic development efforts without the need for extensive internal resources. Under the agreement, Angios will retain rights to develop and commercialize resulting therapies, while AbCellera will receive equity, research fees, milestone payments, and royalties.
AbCellera (Nasdaq: ABCL) announced that its second antibody, LY-CoV1404, has commenced clinical trials for treating patients with mild-to-moderate COVID-19. The ongoing BLAZE-4 trials, conducted with Eli Lilly, will assess LY-CoV1404 both solo and in combination with other antibodies. Preclinical results demonstrate that LY-CoV1404 effectively binds to a stable region of the SARS-CoV-2 spike protein, neutralizing all known variants of concern. This potent antibody may enable lower clinical dosing and potentially subcutaneous administration, supporting its role in combating COVID-19 long-term.
AbCellera (Nasdaq: ABCL) has commenced construction on an expanded global headquarters in Vancouver, aiming to grow its workforce from 250 to hundreds over the next few years. The new tech campus will span 380,000 square feet and is projected for completion in 2023 and 2024. CEO Carl Hansen emphasized that the facilities will accelerate antibody therapy development in collaboration with global biotech and pharma partners. This development solidifies Vancouver's position as an innovation hub and supports AbCellera's long-term goal of establishing Canada's first clinical-grade antibody manufacturing facility.
AbCellera (Nasdaq: ABCL) will release its first-quarter 2021 financial results on May 13, 2021, and host an earnings conference call at 2:00 p.m. PT (5:00 p.m. ET). A live webcast will be accessible via the Investor Relations website, with a replay available afterward.
AbCellera specializes in antibody discovery by analyzing immune systems, partnering with various drug developers to streamline drug development processes.
AbCellera (Nasdaq: ABCL) and Empirico Inc. announced a strategic collaboration focusing on multi-target drug discovery. The partnership utilizes advanced technologies and data analysis to identify therapeutic targets and antibodies. Empirico will select up to five targets using its Precision Insights Platform, while AbCellera will leverage its AI for antibody discovery. AbCellera will receive research payments and may earn royalties from developed products. The collaboration aims to address challenges in drug development by linking human genetics to therapy insights.
AbCellera (Nasdaq: ABCL) announced the publication of preclinical data in Science Translational Medicine demonstrating the high potency of bamlanivimab (LY-CoV555) against SARS-CoV-2. The findings indicate that bamlanivimab significantly reduces viral load post-exposure, highlighting its potential to decrease viral shedding and transmission. In clinical trials, bamlanivimab has shown to cut hospitalizations by 70% in high-risk COVID-19 patients. It has also been authorized in over 15 countries and supports ongoing efforts to develop next-generation antibodies.
AbCellera (Nasdaq: ABCL) has announced an expanded collaboration with Gilead Sciences that includes a multi-year, multi-target antibody discovery initiative and access to AbCellera's Trianni Mouse® technology. The agreement entails upfront payments, milestone payments, and royalties based on the commercialization of antibodies developed. AbCellera will produce panels of antibodies for up to eight new targets across various indications, enhancing drug development efficiency with advanced technology.
AbCellera (Nasdaq: ABCL) announced positive results from a Phase 3 trial of bamlanivimab and etesevimab, reducing COVID-19-related hospitalizations and deaths by 87% in high-risk patients. No deaths occurred in the treatment group, while 14 were reported in the placebo cohort. Milestones achieved include Emergency Use Authorization from the FDA and expanded access in the EU. The study involved 769 patients, showing a safety profile consistent with earlier trials. Bamlanivimab was the first COVID-19 therapeutic candidate to receive FDA EUA.